Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home

Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, today announced that it has entered into a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop a diagnostic device that will enable hemophilia patients to determine their coagulation status at home.

Hemophilia is a rare genetic disorder that affects approximately 400,000 worldwide.1 Those with hemophilia lack sufficient blood-clotting proteins, including factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia. This condition is complex to manage, but many patients do so through home therapy and often only see their core multidisciplinary healthcare team yearly.1 There is therefore an increasing need for patients to be able to monitor their condition more efficiently at home while staying connected with their care team. This is what Enzyre and Takeda are trying to achieve through their collaboration.

Read more